Interestingly, the pattern of an acute reduction followed by a stabilization in GFR reported in study 1 and study 2 in the SGLT2 inhibitors groups [7–10] is similar to those reported with angiotensin-converting enzyme inhibitors (ACEi) in subjects with CKD but with different underlying mechanisms for the changes in GFR. The gene discussed is SLC5A2; the disease is chronic kidney disease.